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of Nephrology, the First Afﬁliated Hospital of Shenzhen University, Shenzhen, China; and 4Centre for Nephrology, University
College London, London, UKIgA nephropathy (IgAN) represents the most common form of primary glomerulonephritis worldwide,
especially in East Asia; even with current treatments, it can lead to end-stage renal disease within 10 years in
approximately 20% of adult patients. Genome-wide association studies in IgAN have identiﬁed susceptibility
genes that are involved in the maintenance of the intestinal epithelial barrier, intestinal inﬂammation, and the
intestinal response to mucosal pathogens, indicating a gutkidney connection. However, the role of gut
microbiota in mediating gutkidney communication is still underappreciated. Here we highlight current
clues that link microbiota with IgAN, and suggest contact points where the microbiota may exert its inﬂuence
on the onset and progression of IgAN. More speciﬁcally, bacterial lipopolysaccharide potentially affects
2 essential components involved in IgAN pathogenesis: the overproduction and hypogalactosylation of IgA1.
Short-chain fatty acids can modulate the inﬂammatory process and protect against renal damage; however,
this protection is lost when the intestinal microbiota changes, becomes imbalanced, and becomes dysbiotic.
Gut microbiota is also involved in the production of uremic toxins such as indoxyl sulfate and p-cresyl
sulfate, which may accelerate kidney disease progression.
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leading form of primary glomerulonephritis and a major
cause of end-stage renal disease (ESRD), leading to dial-
ysis and kidney transplantation on a global scale.2 The
predominant feature of this disease is the deposition of
IgA-containing immune complexes in the glomerular
mesangium, along with local inﬂammation, mesangial
proliferation, glomerular ﬁbrosis, and subsequent loss of
kidney function. IgAN can vary signiﬁcantly among
affected individuals in regard to clinical features, renal
biopsy ﬁndings, rate of disease progression, and prog-
nosis. Some patients exhibit only benign hematuria or
mild proteinuria for many years, whereas 30% to 50% of
patients can show rapid progression and develop ESRDspondence: Xiong Z. Ruan and Yongcheng He, AstraZeneca-
hen University Joint Institute of Nephrology, Centre for
ology & Urology, Department of Physiology, University
Science Center; Department of Nephrology, the First
ted Hospital of Shenzhen University, Shenzhen, China.
l: x.ruan@ucl.ac.uk
ved 27 May 2016; revised 30 July 2016; accepted 2 August
published online 6 August 2016
International Reports (2016) 1, 189–196within 20 years. Although 4 large-scale genome-wide
association studies (GWAS)3–6 have been performed that
examined IgAN, the loci discovered could explain only a
relatively small proportion (about 6%8%) of the
overall disease risk.6 To date, the etiology of IgAN is only
partially deﬁned, and the triggering event(s) is even less
well understood.
It has been demonstrated that the mucosal immune
system, including the gastrointestinal mucosa, plays an
essential part in the pathogenesis of IgAN (reviewed
elsewhere7), and it is now widely accepted that the gut is
an important source of chronic inﬂammation in chronic
kidney diseases (CKD)8. Most GWAS-identiﬁed IgAN
susceptibility genes are directly or indirectly related to
the risk of inﬂammatory bowel disease (IBD),6 indicating
a potential role for a gutkidney connection in the
development of IgAN. However, the speciﬁc factors that
elicit mucosal immune dysregulation, stimulate gut
inﬂammation, and/or initiate intestine-to-kidney cross-
talk remain inconclusive. Increasing evidence suggests
that the gut microbiota is an important triggering factor.
The human intestinal tract is home to more than
100 trillion microorganisms collectively as the gut189
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microbiota contributes to the host’s nutrient absorption,
metabolic activity, and immune homeostasis. Thus far,
the bidirectional inﬂuence between intestinal micro-
biota and renal disease has been proposed by several
studies. For example, metabolites of beneﬁcial bacteria,
short-chain fatty acids (SCFAs), can modulate inﬂam-
matory via epigenetic modiﬁcation, and play a protec-
tive role in ischemia-reperfusion induced acute kidney
injury.9 However, other potentially toxic bacterial me-
tabolites such as p-cresol sulfate and indoxyl sulfate are
also well-known uremic toxins and can elicit the release
of pro-inﬂammatory cytokines and thereby accelerate
kidney injury. Gut microbiotaderived trimethylamine
N-oxide not only takes part in the development of
atherosclerosis but has also been implicated in CKD
progression. Lipopolysaccharide (LPS), derived from the
cell wall of Gram-negative bacteria, is highly correlated
with the severity of systemic inﬂammation, even
without clinically detectable infection. LPS involvement
in the hyperproduction and hypogalactosylation of
IgA1 has also been described. On the other hand, it is
likely that renal dysfunction can, either directly or
indirectly, affect the composition of the intestinal
microbiota, as well as the intestinal mucosal barrier.
In contrast to previous reviews, here we highlight the
growing body of basic and clinical evidence that connect
the pathogenesis and progression of IgAN to the gut
microbiota. A better understanding of gut microbiota’s
inﬂuence on the development of IgAN would greatly
facilitate our exploration of new diagnostic, therapeutic,
and prognostic approaches to targeting these bacteria.
Clinical and Genetic Evidence Indicate Gut-
Kidney Connection in IgAN
The susceptibility of IgAN dramatically changes by
geographic region and race/ethnicity. The IgAN prev-
alence, based on renal biopsy registries, is estimated to
be 5% in the Middle East,10,11 10%–35% in Europe,12–16
and up to 50% in East Asia (mainly Japan17 and
China18). The incidence of ESRD among Asian Ameri-
cans is 4-fold higher compared with that in European
Americans, and is almost 7-fold higher compared with
that in African Americans.19 In addition, several in-
vestigations reported a familial aggregation tendency
for IgAN.20–25 Close relatives of IgAN patients tend to
have higher risk of urinary abnormalities,26 as well as
higher levels of galactose-deﬁcient IgA1 in their cir-
culation.27 All of these observations indicate that
genetic background makes a substantial contribution
to the development of this disease.
To explore the molecular mechanisms that underlie
disease heritability, genome-wide linkage analysis has
been applied to IgAN,28,29 as have GWASs. To date, 4190large-scale GWASs3–6 have identiﬁed distinct IgAN
susceptibility loci (Table 1). These risk alleles could
partially explain the geographical distribution of IgAN
and provide insight about key factors involved in IgAN
pathogenesis. However, GWASs could explain only a
relatively small proportion (approximately 6%-8%) of
the overall disease risk.6 It is worth noting that most
IgAN risk alleles take part in physiological processes
involving intestinal inﬂammation, maintenance of the
intestinal epithelial barrier, and production of intestinal
mucosal IgA in response to microbial antigens. These
risk genes are, either directly or indirectly, associated
with IBD, suggesting a strong gutkidney connection in
the pathogenesis and progression of IgAN, as well as a
potential role of the microbiota as a triggering factor.
There are more clinical observations to support the
gutkidney axis hypothesis. Kidney involvement is
common in patients with gastrointestinal disease. A
high frequency of IgAN has been reported among
patients with Crohn’s disease and ulcerative colitis
(2 main forms of IBD).30 A large number of patients
with IBD have increased numbers of IgA-producing
cells in the gut, as well as elevated serum IgA levels
and hematuria.31 About 20% of IBD patients also have
various kinds of renal diseases, including ﬁstula, uro-
lithiasis, tubular lesion, and a small chance of glomer-
ulonephritis.7 It has been described in several case
reports that successful treatment of inﬂammatory coli-
tis can lead to disappearance of glomerular IgA depo-
sition and to remission of mesangial proliferation.32
Conversely, it has been reported that patients with
IgAN can show abnormal duodenal histopathological
patterns,33 or signs of intestinal inﬂammation.34
The relevance of celiac disease (CD) to IgAN repre-
sents another research topic regarding a gutkidney
connection. Patients with IgAN show increased intes-
tinal permeability and higher mucosal sensitivity to
food antigens (such as gluten) in general.35 The pres-
ence of high levels of IgA against food antigens has
raised the issue of a potential pathophysiological asso-
ciation between IgAN and CD. Although several hy-
potheses postulate that food antigens may be involved
in the triggering of IgAN, experimental IgAN can be
induced by dietary gliadin or gluten in mice.36 In
sparse clinical cases, the introduction of a gluten-free
diet in IgAN patients has led to favorable outcomes37
or complete clinical remission.38 However, more
studies on the co-occurrence of IgAN and CD have
yielded inconsistent results. In a study by Welander
et al.,39 7 of 27,160 CD patients (0.026%) were found to
have developed IgAN. Although this prevalence was 3-
fold higher than that in the control cohort (0.008%),
the incidence of IgAN among individuals with CD was
extremely low. In a study by Collin et al.,40 8 of 223Kidney International Reports (2016) 1, 189–196
Table 1. IgA nephropathy susceptibility genes identiﬁed by genome-
wide association studies6
Risk locus Gene Function
1p13 VAV3 VAV3 encodes guanine nucleotide exchange factors
essential for adaptive immune function, colonic
enterocyte differentiation, and IgA production.
1q32 CFHR1/3 (deletion) CFHR1/3 encodes Factor Hrelated peptides that
modulate the activity of the alternative
complement pathway.
6p11 ITGAM, ITGAX ITGAM and ITGAX encode integrins aM and aX mark
intestinal dendritic cells that maintain a balance
between inﬂammation and tolerance
6p21 TAP1, TAP2,
PSMB8, PSMB9
encode interferon-induced subunits of the
immunoproteosome that mediate intestinal
nuclear factorkB activation in inﬂammatory
bowel disease
6p21 HLA-DP Major histocompatibility complex class II molecules,
implicated in immune regulation
8p23 DEFA1, DEFA3,
DEFA5, DEFA6
DEFA gene clusters encode anti-microbial peptides,
a-defensins, and provide innate defense against
microbial pathogens
9q34 CARD9 CARD9 involves in both innate and adaptive immune
responses by regulate intestinal nuclear factorkB
activation; CARD9 mediates intestinal repair and
bacterial infection after intestinal epithelial injury
17p13 TNFSF13 TNFSF13 encodes APRIL, a powerful B-cellstimulating
cytokine that is induced by intestinal bacteria and
involves in IgA class switching
22q12 HORMAD2 The risk allele has a protective role against Crohn’s
disease (1 of the main forms of inﬂammatory
bowel disease)
Adapted from Kiryluk K et al. Nat Genet. 2014;46:1187–1196, and Feehally J.
Nat Rev Nephrol. 2016;12:147-156.
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searchers thus hypothesized that IgAN patients are
predisposed genetically to be susceptible to CD. In
another study, Moeller et al.41 tested 99 biopsy-proven
IgAN patients and 96 unaffected controls matched for
age and sex. However, the levels of CD-characteristic
serologic markers (for example, IgG and IgA anti-
bodies to gliadin and transglutaminase 2) showed no
signiﬁcant difference between IgAN patients and un-
affected individuals.
The Multi-hit Pathogenesis Model of IgAN
The origin and composition of IgA-containing immune
complexes are key issues in relation to IgAN patho-
genesis. However, they are still under debate, despite
years of investigations. The high recurrence rate of
IgAN after transplantation,42 together with the fact that
transplantation of donor kidneywithmesangial deposits
into a recipient without IgAN can lead to the elimination
of mesangial IgA accumulation,43 suggests an extrarenal
cause of IgAN. Because IgA represents the most abun-
dant Ig produced by the mucosal barrier immune sys-
tem, especially in the gastrointestinal tract, it is likely
that the mucosal immune system plays a critical role in
the pathogenesis of IgAN.
There are 2 subclasses of human IgA molecules,
namely, IgA1 and IgA2. IgA1 is the predominateKidney International Reports (2016) 1, 189–196subclass in the circulation of healthy individuals, and
this subclass is also found in circulating immune com-
plexes and mesangial deposits of patients with IgAN.44,45
A number of investigations46–50 have reported the
presence of hypogalactosylated structures at the IgA1
hinge region in IgAN patients, a particular glycosylated
pattern also known as galactose-deﬁcient IgA1 (gd-IgA1).
More speciﬁcally, compared with the IgA1 structure
normally seen in individuals without IgAN, the serum
and mesangial IgA1 of IgAN patients is characterized by
a different pattern of O-glycosylation in the IgA1 hinge
region, with less galactose attached (Figure 1).
A multi-hit pathogenic model of IgAN46,51,52 has
been proposed to explain the IgAN pathogenesis,
integrating current ﬁndings that include gd-IgA1
overproduction, gd-IgA1 autoantibody generation,
IgA1-containing immune complex formation and
deposition, and subsequent complement system acti-
vation (reviewed elsewhere53). According to this
model, there are 4 “hits” during the pathogenesis of
IgAN. In the ﬁrst hit, the excessive production of IgA1
with galactosylation defects results in an elevated Gd-
IgA1 level in the circulation. In the second hit, the
high level of Gd-IgA1 activates an antoimmune
response, leading to the generation of anti-glycan an-
tibodies that recognize N-acetylgalactosamine epitopes
on Gd-IgA1. Binding of Gd-IgA1 and anti-glycan an-
tibodies leads to the formation and deposition of IgA1-
containing immune complexes in the glomerular
mesangium, which is the third hit. Finally, the fourth
hit is the stimulation of mesangial proliferation by the
immune deposits, as well as local production of cyto-
kines such as interleukin-6 (IL-6) and transforming
growth factorb (TGF-b)54,55, with local inﬂammation
and complement system activation. Although this
model is something of an oversimpliﬁcation, it provides
a plausible conceptual framework for describing the
sequence of pathogenic events, and one that the
available GWAS data can help to reﬁne.45,46
According to this framework, the overproduction
and hypogalactosylation of IgA1 in the ﬁrst hit, which
together lead to an elevated level of circulating
Gd-IgA1, are central to the disease process. Although
Gd-IgA1 might need co-factors to trigger the initiation
of immune complexes,27,56 it represents an indispens-
able part of IgAN pathogenesis. We discuss the inﬂu-
ence of gut microbiota on Gd-IgA1 later.
The Gut Microbiota and Microbiome
There are more than 100 trillion microbial cells that
colonize our gastrointestinal tract, which comprise the
gut microbiota. This intestinal microbiome constitutes
a symbiotic ecosystem that co-evolved with the host.
Under physiological conditions, 6 bacterial phyla,191
Figure 1. Galactosylation patterns of IgA1 hinge region under physiological conditions and under IgA nephropathy (IgAN). Under physiological
conditions, N-acetyl-galactosamine (GalNAc) is attached to the oxygen atom of a serine (Ser) or threonine (Thr) by a polypeptide transferase
GALNT enzyme. A galactose is then added to the O-glycoside via b1,3-galactosyltransferase. Galactosylated O-glycoside can be further
sialylated by sialyltransferase in 3 different forms or can remain free of N-acetylneuraminic acid (NeuNac). In IgA nephropathy, the most
predominant abnormalities are defective galactose fixation or forward GalNAc sialylation.
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Actinobacteria, Fusobacteria, and Verrucomicrobia,
dominate our gut microbiota; among them the phyla
Bacteroidetes and Firmicutes contribute more than 90%
of all species.
The microbiota participate in important metabolic
activities of the host, including digestion of complex
polysaccharides,57,58 regulation of the immune sys-
tem,59–61 synthesis of certain endogenic vitamins and
amino acids,62 and metabolism of bile acids,63 among
others. The symbiotic ecosystem also confers protection
against infection by potential pathogens by competing
with exotic microorganisms. The maintenance of an
appropriate mix of probiotics and opportunistic path-
ogen is essential to the health of the host. In recent
years, the development of next-generation sequencing
applied to the gut microbiota, including 16S rRNA
sequencing, metagenome sequencing, and metatran-
scriptome sequencing, has provided a great opportu-
nity for identifying the composition and function
of bacteria in the human gut and investigating its
association with human health. There is increasing
evidence that altering the balance of the gut
microbiota can profoundly affect human health
and disease. The gut microbiome plays an important
role in IBD,64 obesity,65 type 2 diabetes,66 type 1
diabetes,67 rheumatoid arthritis,68 colorectal cancer,69,70
and cardiovascular disease.71,72 It also seems reasonable
to speculate that the same may be true for IgAN.192The Role of the Gut Microbiota in IgAN
A bidirectional inﬂuence between the intestinal
microbiota and kidney diseases has been proposed.73
Gut microbiotaderived metabolites, such as SCFAs,
and uremic toxins p-cresol sulfate and indoxyl sulfate,
have either anti-inﬂammatory or pro-inﬂammatory ef-
fects, and play substantial roles in the development and
progression of acute kidney injury and CKD. The
translocation of bacterial products (LPS, metabolites, or
the bacteria themselves) across the intestinal barrier-
activates the innate immune response, and enhances
the systematical inﬂammatory response that can be
linked to IgAN, CKD, and ESRD.73
A small number of studies have directly focused on
the relationship between renal disease and the gut mi-
crobials. Vaziri et al. analyzed the intestinal microbial
ﬂora of 24 patients with ESRD compared with 12
healthy controls, and identiﬁed bacteria from the
Brachybacterium, Catenibacterium, Enterobacteriaceae,
Halomonadaceae, Moraxellaceae, Nesterenkonia, Poly-
angiaceae, Pseudomonadaceae, and Thiothrix families
that showed a remarkable increase in patients with
ESRD.74 Further investigation conﬁrmed that, compared
with healthy controls, ESRD patients showed signiﬁ-
cant expansion of urease, uricase, indole-producing
and p-cresolproducing bacteria, and reductions in
SCFA-producing bacteria.75 De Angelis et al. also
described the intestinal microbiota and metabolome
composition differences among IgAN progressors andKidney International Reports (2016) 1, 189–196
L Han et al.: IgA Nephropathy and Gut Microbiota MEETING REPORTnonprogressors, as well as healthy controls.76 Current
studies are still in their infancy, with limited in-
vestigations as well as limited sample size, and further
basic and clinical investigations will be necessary to
establish a relevant or causal biological association
between gut microbiota and renal disease.
Gut MicrobialDerived LPSs Alter the Produc-
tion and Galactosylation of IgA1
As outlined in the multi-hit pathogenesis model,
overproduction of hypogalactosylated IgA1 may play
an essential role in the development of primary IgAN
and may be associated with faster progression of kid-
ney disease.77 In this section, we consider the gut
microbiota’s inﬂuence on the production and gal-
actosylation of IgA.
IgA production can be T-cell dependent.7 In response
to T-cell regulation, B cells mature into plasma cells and
reach the mucosal lamina propria, releasing 2 forms of
dimeric IgA1 or IgA2. Either form can bind to other IgA
molecules of the same kind, forming dimeric IgA (dIgA)
or polymeric IgA (pIgA) proteins. dIgA or pIgA can
bind to the polymeric Ig receptor (pIgR) that is located
on the basolateral surface of the mucosal epithelium;
dIgA or pIgA is then transported from the basolateral
surface to the apical surface by transcytosis. dIgA
then detaches from pIgR but retain the pIgR
secretory component, constituting the dominant
mucosal secretory form of IgA (sIgA). IgA production
can also be modulated by T-cellindependent mecha-
nisms. In this condition, epithelial cells, stromal cells,
and dendritic cells secrete cytokines such as
interleukin-6 (IL-6), interleukin-10 (IL-10), trans-
forming growth factorb (TGF-b), tumor necrosis
factor ligand superfamily member 13B (TNFSF13B, also
known as B-cellactivating factor [BAFF]), and so forth.
These cytokines activate plasma cell maturation and
promote class switching from IgM to IgA1.
Recurrent or chronic bacterial infections can
potentially stimulate the mucosal immune response,
promoting IgA production, and are considered patho-
genic triggers in IgAN. Even without exogenous in-
vasion, commensal bacterial dysbiosis and overgrowth
of harmful bacteria would activate T-celldependent
IgA production, stimulating the overproduction of
IgA. In addition, possible associations between LPS
exposure and hypogalactosylation of IgA have been
reported. A study by Qin et al. showed that bacterial
LPS activated TLR4 in cultured peripheral B lympho-
cytes from patients with IgAN as well as from healthy
controls, inducing methylation of the chaperone
Cosmc, which is essential for the activity of gal-
actosyltransferase, reducing its activity and hence the
galactosylation of IgA1.78Kidney International Reports (2016) 1, 189–196Gut MicrobialGenerated SCFAs Have a
Protective Role in Renal Injury
SCFAs are the main metabolites produced by certain
colonic anaerobic bacteria by the fermentation of di-
etary ﬁber and resistant starches. SCFAs are a subset of
organic fatty acids with 1 to 6 carbons: acetate (2C),
propionate (3C), and butyrate (4C) constitute the most
abundant SCFAs. Although SCFAs are essentially waste
products for the microbes, they have been shown to
have physiological functions and to play an important
role in the maintenance of health and the development
of disease. Available evidence demonstrates that SCFAs
serve as nutrients for colonic epithelia (i.e., colono-
cytes), regulate intracellular pH,79 modulate blood
pressure,80 and have anti-inﬂammatory, antimicrobial,
as well as antitumorigenic roles.81
Two important SCFA signaling mechanisms have
been identiﬁed, namely, inhibition of histone deace-
tylases (HDACs) and activation of G-proteincoupled
receptors (GPCRs). In a series of well-designed experi-
ments, Andrade-Oliveira et al.9 showed that treatment
with SCFAs, especially acetate, can reduce ischemia-
reperfusion kidney injury. It is tempting to hypothe-
size that, other than providing an energy source to the
kidney, SCFAs may reduce inﬂammation and may
promote apoptosis to decrease energy consumption,
diverting energy toward cellular regeneration. As re-
ported in a previous study,75 patients with ESRD
showed signiﬁcant reductions in SCFA-producing
bacteria, which may relate to the loss of the reno-
protective effect of SCFAs. However, another study
reported that oral administration of SCFAs at elevated
levels in mice resulted in dysregulated T-cell responses
and tissue inﬂammation of the renal system.82
Given the fact that SCFAs can act either as immune
tolerance promoters or as inﬂammatory inducers, more
experimental studies and clinical trials are needed to
fully address the inﬂuence of SCFAs on IgAN.
Gut MicrobialProduced Uremic Toxins
Accelerate Kidney Disease Progression
Patients with CKD or ESRD have progressively elevated
levels of plasma uremic toxins. Certain intestinal bac-
teria can produce advanced glycation end-products
with uremic toxins, including phenols82 and in-
doles.83 Aronov et al.84 compared plasma from hemo-
dialysis patients with and without intact colons,
and conﬁrmed the colonic origin of 5 uremic solutes:
a-phenylacetyl-l-glutamine, 5-hydroxyindole, indoxyl
glucuronide, p-cresol sulfate, and indoxyl sulfate.
These are prototypical members of a large group of
protein-bound uremic toxins that are resistant to
clearance by dialysis.85 Animal studies have shown
that the biological effect of these molecules includes193
Figure 2. Possible roles of dysbiotic intestinal microbiota in the development of IgA nephropathy (IgAN). The dysbiotic intestinal microbiota
leads to contraction of short-chain fatty acidproducing intestinal microbiota, and overgrowth of uremic toxinforming bacteria. Gut
microbiotaderived endotoxin is involved in the hyperproduction and hypogalactosylation of IgA1 and thus substantiality contributes to the
development of IgAN. LPS, lipopolysaccharide.
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stimulation, and endothelial dysfunction, thus playing
a potentially substantial role in the development and
progression of multiple causes of acute kidney injury
and CKD. Moreover, gut-derived trimethylamine
N-oxide is not only considered to be an independent risk
factor for cardiovascular disease71,72 but is also related to
CKD progression and mortality.86 Investigations high-
light the role of uremic toxinproducing gut bacteria
and their potential as therapeutic targets.
Conclusion
Increasing evidence from clinical, genetic, epigenetic,
and immunologic studies support a role for gut
microbiota dysbiosis in the pathogenesis and progres-
sion of IgAN (Figure 2). Bacterial LPS can elicit a sys-
temic inﬂammatory response and is implicated in the
hyperproduction and hypogalactosylation of IgA1. The
renal protective role of SCFAs can be lost when the
balance of microbiota changes. Gut microbes that pro-
duce uremia toxins such as p-cresol sulfate, indoxyl
sulfate, and trimethylamine N-oxide may increase CKD
progression, whatever the underlying cause.
Technological developments in high-throughout
sequencing, metagenomic sequencing, and metab-
olomic proﬁling offer an unprecedented opportunity to
identify and to deﬁne the patterns of gut microbiota
that occur in, and may inﬂuence, disease. It will be
worthwhile to carry out microbiome and metabolome
analyses in IgAN patients compared with healthy
controls to determine whether there is an association
between IgAN-related gut microbiota and disease
phenotype. If the IgAN-related microbiota can be
administered to germ-free animals and can be shown to194induce disease, this would strengthen the likely causal
relationship between the intestinal microbiota and
IgAN pathogenesis. The aim of identifying gut micro-
organism biomarkers for early diagnosis of and therapy
for IgAN is another worthwhile goal.
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